Literature DB >> 15140777

High production of proinflammatory and Th1 cytokines by dendritic cells from patients with rheumatoid arthritis, and down regulation upon FcgammaR triggering.

T R D J Radstake1, P L E M van Lent, G J Pesman, A B Blom, F G J Sweep, J Rönnelid, G J Adema, P Barrera, W B van den Berg.   

Abstract

OBJECTIVE: To assess whether DC from RA produce altered cytokine levels and whether this is regulated by triggering of Fc gamma receptors (FcgammaR).
METHODS: The production of proinflammatory (TNFalpha, IL1, IL6), Th1 (IL12, IFNgamma), and Th2 (IL10) cytokine profiles of immature DC (iDC) from patients with RA and healthy subjects upon triggering of FcgammaR dependent and independent pathways was investigated. iDC, derived from blood monocytes by standardised protocols, were stimulated with immune complexes (IC) at day 6 for 48 hours and, subsequently, for 2 days with LPS in the presence or absence of IC or IFNgamma, resulting in fully matured DC (mDC). IL1, IL6, TNFalpha, IFNgamma, IL12, and IL10 levels in supernatants were measured by ELISA and RIA.
RESULTS: mDC from patients with RA showed a markedly increased production of IL1, IL6, TNFalpha, and IL10 compared with DC from healthy donors. Triggering of FcgammaR decreased the production of proinflammatory cytokines IL1, IL12, and IFNgamma by iDC and mDC in RA and controls. The production of IL6 and TNFalpha decreased in patients with RA, whereas it was increased in controls. Triggering of FcgammaR independent mechanisms using IFNgamma increased the production of proinflammatory and Th1 cytokines, which was more pronounced in RA.
CONCLUSION: FcgammaR dependent pathways influence cytokine production by DC. A skewed balance towards proinflammatory and Th1 cytokines in RA can, at least partly, be restored by triggering FcgammaR on DC in RA. Insight into the mechanism which determines the FcgammaR balance might lead to new strategies to abrogate Th1 driven inflammatory processes in RA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15140777      PMCID: PMC1755036          DOI: 10.1136/ard.2003.010033

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  50 in total

1.  Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses.

Authors:  T B Geijtenbeek; R Torensma; S J van Vliet; G C van Duijnhoven; G J Adema; Y van Kooyk; C G Figdor
Journal:  Cell       Date:  2000-03-03       Impact factor: 41.582

Review 2.  Fc receptor signaling and trafficking: a connection for antigen processing.

Authors:  S Amigorena; C Bonnerot
Journal:  Immunol Rev       Date:  1999-12       Impact factor: 12.988

Review 3.  The role of cytokines in the pathogenesis of rheumatoid arthritis.

Authors:  M Feldmann; R N Maini
Journal:  Rheumatology (Oxford)       Date:  1999-11       Impact factor: 7.580

4.  Increased expression of Fcgamma receptors II and III on macrophages of rheumatoid arthritis patients results in higher production of tumor necrosis factor alpha and matrix metalloproteinase.

Authors:  Arjen B Blom; Timothy R D J Radstake; Astrid E M Holthuysen; Annet W Slöetjes; Gerard J Pesman; Fred G J Sweep; Fons A J van de Loo; L A B Joosten; Pilar Barrera; Peter L E M van Lent; Wim B van den Berg
Journal:  Arthritis Rheum       Date:  2003-04

5.  Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera.

Authors:  M Helle; L Boeije; E de Groot; A de Vos; L Aarden
Journal:  J Immunol Methods       Date:  1991-04-08       Impact factor: 2.303

Review 6.  Rheumatoid factors in immune complexes of patients with rheumatoid arthritis.

Authors:  M Mannik; F A Nardella; E H Sasso
Journal:  Springer Semin Immunopathol       Date:  1988

7.  Induction of tumor necrosis factor alpha production by adhered human monocytes: a key role for Fcgamma receptor type IIIa in rheumatoid arthritis.

Authors:  V M Abrahams; G Cambridge; P M Lydyard; J C Edwards
Journal:  Arthritis Rheum       Date:  2000-03

8.  Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis.

Authors:  G S Firestein; D L Boyle; C Yu; M M Paine; T D Whisenand; N J Zvaifler; W P Arend
Journal:  Arthritis Rheum       Date:  1994-05

9.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

Authors:  M J Elliott; R N Maini; M Feldmann; J R Kalden; C Antoni; J S Smolen; B Leeb; F C Breedveld; J D Macfarlane; H Bijl
Journal:  Lancet       Date:  1994-10-22       Impact factor: 79.321

10.  Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells.

Authors:  Alexis M Kalergis; Jeffrey V Ravetch
Journal:  J Exp Med       Date:  2002-06-17       Impact factor: 14.307

View more
  16 in total

Review 1.  Dendritic cells, Fc{gamma} receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis.

Authors:  T R D J Radstake; A W T van Lieshout; P L C M van Riel; W B van den Berg; G J Adema
Journal:  Ann Rheum Dis       Date:  2005-05-05       Impact factor: 19.103

2.  Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions.

Authors:  Adam M Boruchov; Glenn Heller; Maria-Concetta Veri; Ezio Bonvini; Jeffrey V Ravetch; James W Young
Journal:  J Clin Invest       Date:  2005-09-15       Impact factor: 14.808

3.  Dendritic cells from patients with rheumatoid arthritis lack the interleukin 13 mediated increase of Fc gamma RII expression, which has clear functional consequences.

Authors:  T R D J Radstake; K C A M Nabbe; M H Wenink; M F Roelofs; A Oosterlaar; A W T van Lieshout; P Barrera; P L E M van Lent; W B van den Berg
Journal:  Ann Rheum Dis       Date:  2005-05-05       Impact factor: 19.103

4.  Therapeutic effect of ergotope peptides on CIA by down-regulation of inflammatory and Th1/Th17 responses and induction of regulatory T cells.

Authors:  Xiaoyin Niu; Shaohua Deng; Shan Li; Yebin Xi; Chengzhen Li; Li Wang; Dongyi He; Zhaojun Wang; Guangjie Chen
Journal:  Mol Med       Date:  2016-08-30       Impact factor: 6.354

5.  Increased expression of CCL18, CCL19, and CCL17 by dendritic cells from patients with rheumatoid arthritis, and regulation by Fc gamma receptors.

Authors:  T R D J Radstake; R van der Voort; M ten Brummelhuis; M de Waal Malefijt; M Looman; C G Figdor; W B van den Berg; P Barrera; G J Adema
Journal:  Ann Rheum Dis       Date:  2004-08-26       Impact factor: 19.103

6.  Inhibition of TNF alpha during maturation of dendritic cells results in the development of semi-mature cells: a potential mechanism for the beneficial effects of TNF alpha blockade in rheumatoid arthritis.

Authors:  A W T van Lieshout; P Barrera; R L Smeets; G J Pesman; P L C M van Riel; W B van den Berg; T R D J Radstake
Journal:  Ann Rheum Dis       Date:  2004-07-15       Impact factor: 19.103

7.  Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab.

Authors:  Christophe Richez; Thierry Schaeverbeke; Chantal Dumoulin; Joël Dehais; Jean-François Moreau; Patrick Blanco
Journal:  Arthritis Res Ther       Date:  2009-06-29       Impact factor: 5.156

8.  Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis.

Authors:  Rachel A Harry; Amy E Anderson; John D Isaacs; Catharien M U Hilkens
Journal:  Ann Rheum Dis       Date:  2010-06-15       Impact factor: 19.103

Review 9.  Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?

Authors:  C M U Hilkens; J D Isaacs
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

10.  Soluble immune complexes shift the TLR-induced cytokine production of distinct polarized human macrophage subsets towards IL-10.

Authors:  Carmen A Ambarus; Kim C M Santegoets; Lenny van Bon; Mark H Wenink; Paul P Tak; Timothy R D J Radstake; Dominique L P Baeten
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.